For a study, researchers sought to characterize the results linked with the use of monoclonal antibodies in pregnant women with mild-to-moderate coronavirus illness in 2019. (COVID-19). From April 1, 2021, to October 16, 2021, they described a retrospective case series of pregnant women who received anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibody infusions at a single facility. Patients who were pregnant and had a positive SARS-CoV-2 polymerase chain reaction (PCR) test result, as well as mild-to-moderate COVID-19 symptoms, were eligible for monoclonal antibody infusion. The need for supplemental oxygen, hospitalization owing to COVID-19, and a positive SARS-CoV-2 PCR test more than 7 days before screening were all exclusion factors for delivery. Based on product availability and dosing instructions, as well as growing resistance trends in the community, all patients got either bamlanivimab plus etesevimab or casirivimab plus imdevimab.
Among 450 people were given monoclonal antibody infusions at the facility over the research period, with 15 of them pregnant. Six (40%) of the 15 pregnant women receiving monoclonal antibodies were fully vaccinated at the time of infusion. 2 patients (13%, CI 0–31%) had systemic responses during the infusion, resulting in transient abnormalities in the fetal heart rate tracing that were corrected by maternal and intrauterine resuscitation measures. 1 woman was delivered after the injection due to deteriorating maternal and fetal condition; the remaining patients did not need to be admitted for COVID-19. Pregnant women who received anti–SARS-CoV-2 monoclonal antibody infusions fared well in the case series.
